Skip to main content

How to judge the association of postmenopausal hormone therapy and the risk of breast cancer

Frontiers of Medicine in China volume 4, pages 290–293 (2010)Cite this article

Abstract

The relevance of postmenopausal hormone therapy (HT) for breast cancer risk has been long debated, although it is one of the most important barriers for women to accept HT. Various opinions have been reported from recent randomized clinical trials and epidemiological studies. These unanswered questions include: whether HT has a positive impact on breast cancer; whether risks of therapy with unopposed estrogen and combined estrogen-progestin are different; and whether different types and routes of estrogen and progestogens, as well as the duration and cessation of HT use, have different impacts on this disorder. Recently, there has been some good news such as the following: the currently available data do not provide sufficient evidence to prove a causal relationship between postmenopausal HT and breast cancer; breast cancer in postmenopausal women using HT usually has better prognosis than that of nonusers. In conclusion, HT is still the most effective method of relieving climacteric symptoms for many postmenopausal women. However, a possible risk of breast cancer associated with long-term HT usage should not be ignored. With respect to prevention of breast cancer, regular evaluation of individual breast cancer susceptibility and close follow-up through mammography and/or breast sonography are necessary strategies for the safety of HT use.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Verkooijen H M, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas, 2009, 64(2): 80–85

    CAS  Article  PubMed  Google Scholar 

  2. Sharpe K H, McClements P, Clark D I, Collins J, Springbett A, Brewster D H. Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy. Eur J Cancer, 2010, 46(5): 937–943

    CAS  Article  PubMed  Google Scholar 

  3. Parkin D M. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer, 2009, 45(9): 1649–1653

    Article  PubMed  Google Scholar 

  4. Katalinic A, Lemmer A, Zawinell A, Rawal R, Waldmann A. Trends in hormone therapy and breast cancer incidence- results from the German Network of Cancer Registries. Pathobiology, 2009, 76(2): 90–97

    Article  PubMed  Google Scholar 

  5. Jemal A, Ward E, Thun M. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res, 2007, 9(3): 108

    Article  Google Scholar 

  6. Canfell K, Banks E, Moa A M, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust, 2008, 188(11): 641–644

    PubMed  Google Scholar 

  7. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progesterone in healthy postmenopausal women. JAMA, 2002, 288(3): 321–333

    Article  Google Scholar 

  8. Huang K E, Xu L, I N N, Jaisamrarn U. The Asian Menopause Survey: knowledge, perceptions, hormone treatment and sexual function. Maturitas, 2010, 65(3): 276–283

    Article  PubMed  Google Scholar 

  9. Gramling R, Eaton C B, Rothman K J, Cabral H, Silliman R A, Lash T L. Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women. Epidemiology, 2009, 20(5): 752–756

    Article  PubMed  Google Scholar 

  10. Pines A, Sturdee D W, Birkhäuser M H, Schneider H P, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric, 2007, 10(3): 181–194

    CAS  Article  PubMed  Google Scholar 

  11. Bush T L, Whiteman M, Flaws J A. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol, 2001, 98(3): 498–508

    CAS  Article  PubMed  Google Scholar 

  12. Chlebowski R T, Hendrix S L, Langer R D, Stefanick M L, Gass M, Lane D, Rodabough R J, Gilligan M A, Cyr M G, Thomson C A, Khandekar J, Petrovitch H, McTiernan A; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA, 2003, 289(24): 3243–3253

    CAS  Article  PubMed  Google Scholar 

  13. Beral V, for the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 2003, 362(9382): 419–427

    CAS  Article  PubMed  Google Scholar 

  14. Anderson G L, Limacher M, Assaf A R, Bassford T, Beresford S A, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard B V, Hsia J, Hubbell A, Jackson R, Johnson K C, Judd H, Kotchen J M, Kuller L, LaCroix A Z, Lane D, Langer R D, Lasser N, Lewis C E, Manson J, Margolis K, Ockene J, O’sullivan M J, Phillips L, Prentice R L, Ritenbaugh C, Robbins J, Rossouw J E, Sarto G, Stefanick M L, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 2004, 291(14): 1701–1712

    CAS  Article  PubMed  Google Scholar 

  15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet, 1997, 350(9084): 1047–1059 Erratum in. Lancet, 1997, 350(9089): 1484

    Article  Google Scholar 

  16. Li C I, Malone K E, Porter P L, Weiss N S, Tang M T, Cushing-Haugen K L, Daling J R. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA, 2003, 289(24): 3254–3263

    CAS  Article  PubMed  Google Scholar 

  17. Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani A R. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol, 2009, 25(12): 807–815

    CAS  Article  PubMed  Google Scholar 

  18. Santen R J. Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones? Womens Health (Lond Engl), 2008, 4(3): 207–210

    CAS  Google Scholar 

  19. Jernström H, Frenander J, Fernö M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer, 1999, 80(9): 1453–1458

    Article  PubMed  Google Scholar 

  20. Nanda K, Bastian L A, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol, 2002, 186(2): 325–334

    CAS  Article  PubMed  Google Scholar 

  21. Chen W Y, Manson J E, Hankinson S E, Rosner B, Holmes M D, Willett W C, Colditz G A. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med, 2006, 166(9): 1027–1032

    CAS  Article  PubMed  Google Scholar 

  22. Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Goldstein L. Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol, 1999, 17(6): 1680–1688

    CAS  PubMed  Google Scholar 

  23. Chlebowski R T, Kuller L H, Prentice R L, Stefanick M L, Manson J E, Gass M, Aragaki A K, Ockene J K, Lane D S, Sarto G E, Rajkovic A, Schenken R, Hendrix S L, Ravdin P M, Rohan T E, Yasmeen S, Anderson G, for the WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med, 2009, 360(6): 573–587

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China

    Ling Xu

Authors
  1. Ling Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ling Xu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Xu, L. How to judge the association of postmenopausal hormone therapy and the risk of breast cancer. Front. Med. China 4, 290–293 (2010). https://doi.org/10.1007/s11684-010-0093-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-010-0093-7

Keywords

  • breast cancer
  • postmenopausal hormone therapy
  • unopposed estrogen therapy
  • combined estrogen-progestin therapy